Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update. Rapid de ...

Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

度普利尤单抗应答不佳的患者，转换阿布昔替尼 200 mg QD*治疗 12 周 EASI-90 和 PP-NRS 0/1 应答率高达 55% 和 43.6%，实现双重高效获益，同时，以更高标准达成 34.7% 的 EASI-90 + PP-NRS 0/1 复合终点，60.9% 达 DLQI ≥ 4，快速迈向「无痒愈肤」治疗目标[17]。 图 5：度普利尤单抗 ...

Select secondary endpoints evaluated at 36 weeks included: Proportion of patients achieving ≥90% reduction in Bullous Pemphigoid Disease Area Index (BPDAI; scale: 0-360) Proportion of patients with ≥4 ...

Proportion of patients with ≥4-point reduction in Peak Pruritus Numerical Rating Scale (PP-NRS; scale 0-10) score Total cumulative OCS dose Time to first use of rescue medication Dupixent ...

根据 T2T 概念，瘙痒的最佳 6 个月治疗目标是患者报告的峰值瘙痒数字评定量表（Peak Pruritus Numeric Rating Scale，PP-NRS）评分≤4 分。 那么，在实际治疗中，这些 “小目标” 能否实现呢？来自多个国家研究机构的研究人员，如德国明斯特大学医院皮肤科、美国 ...

尊敬的患者朋友及家属： 目前正在开展一项“评价QY201片在中重度特应性皮炎受试者中有效性和安全性的多中心、随机、平行、双盲、安慰剂对照的 ...